Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder

Movement Disorders

Volumn 20, Issue 1, 2005, Pages 105-108

  Happe, Svenja ^a   Sommer, Martin ^a   Meller, Johannes ^a   Trenkwalder, Claudia ^a   Paulus, Walter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apomorphine; Choreatiform dyskinesia; Drug induced dyskinesia; Psychogenic parkinsonism

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; QUETIAPINE;

ADULT; AKINESIA; ARTICLE; CASE REPORT; CHOREA; DEPRESSION; DISEASE RESISTANCE; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DYSKINESIA; FEMALE; HUMAN; HYPERKINESIA; PARKINSONISM; PRIORITY JOURNAL; SELF INJECTION; SINGLE DRUG DOSE; TREATMENT FAILURE; TREMOR;

ANTIPARKINSON AGENTS; APOMORPHINE; BASAL GANGLIA; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PARKINSONIAN DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 14044268197     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20274     Document Type: Article

References (16)

1. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today 2003;39:19-49.
2. Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol 2001; 58:1385-1392.
3. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(Suppl. 2):II/43-II/50.
4. Shaibani A, Sabbagh MN. Pseudoneurologic syndromes: recognition and diagnosis. Am Fam Physician 1998;58:1970-1972.
5. Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J Neurol Neurosurg Psychiatry 1995;59:406-412.
6. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995;52:802-810.
7. Fahn S, Williams D. Psychogenic dystonia. Adv Neurol 1988;50: 431-455.
8. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl. 7): S28-S33.
9. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.
10. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
11. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997;17:1027-1030.
12. Cummings JL. A window on the role of dopamine in addiction disorders. J Neurol Neurosurg Psychiatry 2000;68:404.
13. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
14. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003;61(Suppl. 3):S4-S11.
15. Pearce RK, Heikkila M, Linden IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology 2001;156:402-409.
16. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.